Search results
Results From The WOW.Com Content Network
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. [ 3 ] [ 4 ] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals , focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.
Novartis is the world's first largest in life sciences and agribusiness markets. [6] It is also the second-largest pharmaceutical company by market cap in 2019. [127] Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. [128]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs.
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Ciprodex, owned by Alcon Laboratories, Inc., is protected by multiple patents and will be restricted from generic manufacturing until 2025. [ 6 ] [ 7 ] Ciprodex is the number 1 topical antibiotic ear drop prescribed since 2007 by ENTs and pediatricians.
More than two years after beginning the acquisition process, Swiss pharmaceutical company Novartis (NVS) said Thursday that it has finally completed the purchase of a 77% majority stake in U.S ...